In the past year or so, new eczema medications have been released that have been highly beneficial for patients. We have seen Eucrisa (crisaborole) New Eczema Medication gets FDA Approval, this is a topical medication which is an inhibitor of phosphodiesterase 4-depndent cyclic adenosine monophosphate degradation. It was approved in 2016 for mild to moderate atopic dermatitis in patients over 2 years of age. It has a low frequency of side effects and it is steroid sparing.
Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers is used to treat moderate to severe eczema and it has been shown to be highly efficacious in moderate to severe atopic dermatitis.
New eczema medications that may be emerging are:
- Tralokinumab, we have discussed previously for asthma. Tralokinumab for Asthma It is an anti-IL-13 agent. It has shown to improve eczema scores given as an injection every 2 weeks and it improved skin clearance. Patients also reported improved quality of life and itching.
- Nemolizumab is an anti-IL-31 receptor A agent. Nemolizumab for Itching and Atopic Dermatitis This has shown promising results in reducing itching in patients with eczema. Itching has implications for sleep disturbance and poor quality of life. In a recent trial, all patients who received nemolizumab had significant reduction in itching. Nemolizumab has shown promising results and remains in the pipeline as a potential future biological therapy.
- Ustekinumab is another agent that targets IL-12/IL-23p40 to suppress TH1, TH17, and TH 22 activation. It has clinical approval for use in patients with psoriasis and has demonstrated clinical efficacy and safety for that condition, but its efficacy and safety for atopic dermatitis are not as well known. Stelara for Plaque Psoriasis Patients with moderate to severe eczema underwent treatment and the results were not very different than those who received placebo. More investigation will be needed for ustekinumab to see if this will have any clinical benefit in the future.
Atopic dermatitis is a very common skin disease and it can affect up to 20% of the population, the majority of patients are children. Great advances have already been made and with more research, we are learning more about the molecular environment of the affected skin. Filaggrin and Thymic Stromal Lymphopoietin are also being studied for potential new eczema medications in the future.